[1]干佳琦,胡梦婷,刘 梅.胺碘酮联合厄贝沙坦对高血压合并房颤患者心率变异性及血清N末端B型钠尿肽前体、基质金属蛋白酶-2、白细胞介素-6水平的影响[J].陕西医学杂志,2023,52(10):1388-1391.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.023]
　GAN Jiaqi,HU Mengting,LIU Mei.Effect of amiodarone combined with irbesartan on heart rate variability and serum NT-proBNP,MMP-2,IL-6 Levels in hypertensive patients with atrial fibrillation[J].,2023,52(10):1388-1391.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.023]
点击复制

胺碘酮联合厄贝沙坦对高血压合并房颤患者心率变异性及血清N末端B型钠尿肽前体、基质金属蛋白酶-2、白细胞介素-6水平的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年10期
页码:
1388-1391
栏目:
药物与临床
出版日期:
2023-10-05

文章信息/Info

Title:
Effect of amiodarone combined with irbesartan on heart rate variability and serum NT-proBNP,MMP-2,IL-6 Levels in hypertensive patients with atrial fibrillation
作者:
干佳琦; 胡梦婷; 刘 梅
(复旦大学附属闵行医院全科医学科,上海 201199)
Author(s):
GAN Jiaqi; HU Mengting; LIU Mei
(Department of General Practice,Minhang Hospital,Fudan University,Shanghai 201199,China)
关键词:
胺碘酮;  厄贝沙坦;  高血压;  阵发性房颤;  心率变异性;  白细胞介素-6
Keywords:
Amiodarone;  Erbesartan;  Hypertension;  Paroxysmal atrial fibrillation;  Heart rate variability;  Interleukin-6
分类号:
R 544.1
DOI:
DOI:10.3969/j.issn.1000-7377.2023.10.023
文献标志码:
A
摘要:
目的:探讨胺碘酮联合厄贝沙坦对高血压合并房颤(PAF)患者心率变异性及血清N末端B型钠尿肽前体(NT-proBNP)、基质金属蛋白酶-2(MMP-2)、白细胞介素-6(IL-6)。方法:选择118例高血压合并阵发性心房颤动患者为研究对象,以随机数字表法将高血压合并阵发性心房颤动患者分为对照组(常规降压+胺碘酮治疗)、观察组(胺碘酮+厄贝沙坦治疗),每组59例。比较两组患者治疗前后血压值及室间隔厚度(IVST)、左室舒张末期内径(LVDd)、左心室后壁厚度(LVPW)、左室重量指数(LVMI)、P波最大值和P波离散度。记录治疗前后患者24 h动态心电图RR间期的标准差(SDNN)、平均值的标准差(SDANN)、相邻RR间期差均方根(rMSSD)、低频率段(LF)、高频率段(HF)变化,并测定血清NT-proBNP、MMP-2、IL-6水平。结果:治疗后,观察组血压值、IVST、LVDd、LVPW、LVMI、P波最大值、IP波离散度及SDNN、SDANN、rMSSD、LF值较对照组下降,HF值较对照组升高,差异有统计学意义(均P<0.05)。治疗后,观察组血清NT-proBNP、MMP-2、IL-6水平显著降低,低于对照组,差异有统计学意义(均P<0.05)。结论:胺碘酮联合厄贝沙坦治疗高血压合并PAF可以改善心率变异性,降低血清NT-proBNP、MMP-2、IL-6水平,延缓或逆转心房重构。
Abstract:
Objective:To investigate the effects of amiodarone combined with irbesartan on heart rate variability and serum N-terminal B-type natriuretic peptide precursor(NT-proBNP),matrix metalloproteinase-2(MMP-2),interleukin-6(IL-6)in patients with hypertension and atrial fibrillation.Methods:A total of 118 patients with hypertension and paroxysmal atrial fibrillation were selected as the study subjects.Using a random number table method,hypertension and paroxysmal atrial fibrillation patients were divided into a control group(conventional antihypertensive+amiodarone treatment)and an observation group(amiodarone+irbesartan treatment),with 59 cases in each group.The blood pressure,interventricular septum thickness(IVST),left ventricular end diastolic diameter(LVDd),left ventricular posterior wall thickness(LVPW),left ventricular mass index(LVMI),P wave maximum and P wave dispersion were compared between the two groups before and after treatment.The standard deviation(SDNN),standard deviation of mean(SDANN),root mean square of adjacent RR interval difference(rMSSD),low frequency segment(LF),and high frequency segment(HF)of RR interval(SDNN)of 24 hour-holter were recorded before and after treatment,and the serum levels of NT-proBNP,MMP-2,and IL-6 were measured.Results:After treatment,the blood pressure,IVST,LVDd,LVPW,LVM,P-wave maximum,P-wave dispersion,SDNN,SDANN,rMSSD,LF values in the observation group were lower than those in the control group,while HF values were higher than those in the control group(all P<0.05).After treatment,the serum levels of NT-proBNP,MMP-2,and IL-6 in the observation group were lower than those in the control group(all P<0.05).Conclusion:The combination of amiodarone and irbesartan can improve heart rate variability,reduce serum NT proBNP,MMP-2,IL-6 levels,and reverse atrial remodeling in hypertensive patients with PAF.

参考文献/References:

[1] 孙婷婷,魏 哲,郑书敏,等.自主神经调控房颤的作用机制及中医药治疗研究进展[J].陕西中医,2019,40(1):135-136.
[2] 胡瑞丹,王晓慧.基于CT首过灌注成像预测冠脉斑块患者左心室重构临床价值研究[J].陕西医学杂志,2022,51(1):41-43.
[3] 应良红,刘海云,朱源生.养心定悸胶囊联合厄贝沙坦治疗高血压合并阵发性心房颤动的临床研究[J].中西医结合心脑血管病杂志,2021,19(13):2222-2225.
[4] 崔玉环,魏玉磊,王大伟,等.老年瓣膜病心房颤动射频消融病人IL-6、NT-proBNP水平变化及临床意义[J].中西医结合心脑血管病杂志,2022,20(10):1868-1870.
[5] 薛春燕,权瑞东.坎地沙坦酯联合阿托伐他汀治疗高血压病合并阵发性房颤疗效及安全性观察[J].贵州医药,2021,45(8):1257-1258.
[6] Jarasunas J,Aidietis A,Aidietiene S.Left atrial strain—an early marker of left ventricular diastolic dysfunction in patients with hypertension and paroxysmal atrial fibrillation[J].Cardiovasc Ultrasound,2018,16(1):29.
[7] 中国高血压防治指南修订委员会.中国高血压防治指南[J].中华高血压杂志,2011,19:701-740.
[8] 郑甲林,张新金,郭 涛,等.甲亢源性心房颤动与肾素-血管紧张素系统相关发病机制的研究[J].现代生物医学进展,2021,21(2):228-232.
[9] 马俊丽,李言鹏,米 琴,等.他汀和肾素-血管紧张素抑制剂对预防心房颤动射频消融术后复发有效性的Meta分析[J].临床心血管病杂志,2018,34(11):1064-1068.
[10] 石晶晶,石树青,胡元会,等.肾素-血管紧张素系统与心房颤动关系研究的可视化分析[J].中国循证心血管医学杂志,2020,12(5):566-571.
[11] 罗 卉.达比加群酯联合阿替洛尔对老年持续性心房颤动患者AngⅡ/Rac1/STAT3通路的影响[J].心血管康复医学杂志,2023,32(1):29-33.
[12] 杨瀚晅,余冬梅,刘益均,等.胺碘酮联合RAS抑制剂对高血压合并心房颤动患者尿酸、SIRT1水平的影响[J].心血管康复医学杂志,2018,27(2):199-203.
[13] Sychov OS,Nesukay G,Stasyshena OV,et al.The state of systolic and diastolic functions of the left ventricle and heart rate variability in patients with atrial fibrillation after infection of COVID-19[J].Eur Heart J,2022,43(2):407.
[14] Sadr-Ameli MA,Izadpanah P,Sadr-Ameli S,et al.Heart rate variability biofeedback in patients with paroxysmal atrial fibrillation[J].Ital Heart J,2021,22(2):68-76.
[15] 李 昭,程泽君,邢新军,等.艾司洛尔联合胺碘酮治疗快速阵发性心房颤动的疗效观察[J].中国医刊,2021,56(5):543-545.
[16] 林 松.替米沙坦联合胺碘酮治疗高血压伴阵发性心房颤动患者疗效及对血清BNP、MMP-2及CTGF水平的影响[J].中国药师,2017,20(6):1055-1058.
[17] 何 芸,张卫卫,孔祥云.血清白细胞介素-6、肿瘤坏死因子-α、活性氧在食管癌术后并发心房颤动患者体内表达水平及检测意义[J].陕西医学杂志,2022,51(7):816-819.
[18] Bijsmans ES,Jepson RE,Wheeler C,et al.Plasma N-terminal probrain natriuretic peptide,vascular endothelial growth factor,and cardiac troponin I as novel biomarkers of hypertensive disease and target organ damage in cats[J].J Vet Intern Med,2017,31(3):650-660.
[19] Darkner S,Goetze JP,Chen X,et al.Natriuretic propeptides as markers of atrial fibrillation burden and recurrence(from the AMIO-CAT trial)[J].Am J Cardiol,2017,120(8):1309-1315.
[20] 屈文涛,康亚宁,许 磊,等.高血压并发阵发性心房颤动患者的左房形变功能与血清NT-proBNP的相关性[J].临床心血管病杂志,2021,37(2):156-160.

备注/Memo

备注/Memo:
基金项目:国家重点研发计划子课题(2019YFF0216502-L21)
更新日期/Last Update: 2023-10-07